


## Errata

Volume 31, No. 8, page 3059: Line 22, of the Results section should read:

less often needed a dose reduction ( $p=0.025$ ) than patients

Volume 32, No. 8, page 3139: Figure 4 should be replaced by the following:



Volume 32, No. 8, page 3140: Line 4, left column, should read:

transduction levels in all human high-grade bladder cancer cells as

Volume 32, No. 8, page 3140: Line 19, left column, should read:

achieve a higher antitumor effect in high-grade bladder cancer cells with

Volume 32, No. 8, page 3140: Line 27, left column, should read:

target high-grade bladder cancer cells, and by applying our findings, it

Volume 32, No. 8, page 3140: Line 29, left column, should read:

strategies for the treatment of high-grade bladder cancer cells.

Volume 33, No. 9, page 4049: Authors and affiliations should read:

AINUR AKILZHANOVA<sup>1,2,3</sup>, ZHANNUR NURKINA<sup>2</sup>, KUVAT MOMYNALIEV<sup>3</sup>,  
ERLAN RAMANCULOV<sup>3</sup>, ZHAXIBAI ZHUMADILOV<sup>2</sup>, TOLEBAY RAKHYPBEKOV<sup>4</sup>,  
NAOMI HAYASHIDA<sup>1</sup>, MASAHIRO NAKASHIMA<sup>5</sup> and NOBORU TAKAMURA<sup>1</sup>

<sup>1</sup>Department of Global Health, Medicine and Welfare,  
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;

<sup>2</sup>Department of Genomic and Personalised Medicine, Center for Life Sciences,  
Nazarbayev University, Astana, Kazakhstan;

<sup>3</sup>National Center for Biotechnology, Astana, Kazakhstan;

<sup>4</sup>Semey State Medical University, Oncology Center, Semey, Kazakhstan;

<sup>5</sup>Department of Tumor and Diagnostic Pathology,  
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;

Volume 34, No. 5, page 2529: Box E5 of Figure 1 should be replaced by the following:

Chest abdominal  
pelvic CT with contrast  
medium for staging  
E5

Volume 34, No. 4, page 1539: Lines 19-23, left column, should read:

In the ongoing phase IIIb AvaALL trial, bevacizumab is used as maintenance therapy after disease progression. Expected results showed an OS beyond PD of 10.1 months in the experimental arm, receiving bevacizumab plus a second-line agent between pemetrexed, docetaxel or erlotinib, versus 7.9 months in the control arm, receiving only the second-line agent chosen by the investigator (43).

Volume 34, No. 5, page 2173: The affiliation superscript number of the last author should be corrected:

CRISTINA MESSA<sup>1,3,4</sup>